Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Product information and disease descriptionPlace of product in therapyDisease description

Pathophysiology

9 evidence topics · 8 sources

Non-islet cell tumor hypoglycemia: incompletely processed big IGF-2 and its bioavailability

“Post-translational modifications of prepro-IGF-2 occur in the Golgi apparatus, where an intermediate molecule comprising the mature IGF-2 domain combined with part of the E-domain is formed and secreted into circulation in small quantities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The expression of high levels of IGF-2 RNA in such tumors results from a loss of imprinting of parent alleles and abnormal activation of promoter regions of the IGF-2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This leads to the production of large quantities of prepro-IGF-2, which oversaturates the prohormone convertase enzyme responsible for converting prepro-IGF-2 to mature IGF-2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Binary complexes, being smaller, can more easily permeate capillary membranes, resulting in higher bioavailability of IGF-2 and a greater potential for hypoglycemic action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The rise in IGF-1 levels suppresses growth hormone (GH) secretion by the pituitary gland, which in turn reduces the production of ALS and IGFBP-3 by the liver. This creates a vicious cycle that further favors the formation of binary complexes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote